Ajaypal Singh to Risk Assessment
This is a "connection" page, showing publications Ajaypal Singh has written about Risk Assessment.
Connection Strength
0.410
-
Message to the FDA on ESAs: REMS is not enough, more studies are needed. Clin J Am Soc Nephrol. 2010 Aug; 5(8):1355-8.
Score: 0.073
-
Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes. Heart Fail Clin. 2010 Jul; 6(3):323-32.
Score: 0.072
-
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.
Score: 0.070
-
Prevention of intravenous contrast-induced nephropathy in hospital inpatients. Crit Pathw Cardiol. 2008 Mar; 7(1):1-4.
Score: 0.061
-
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019 05; 21(5):1199-1208.
Score: 0.033
-
The Prevalence, Clinical Spectrum and the Long Term Outcome of ST-segment Elevation Myocardial Infarction in Young - A Prospective Observational Study. Cardiovasc Revasc Med. 2019 05; 20(5):387-391.
Score: 0.031
-
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type?2 Diabetic Patients With CKD. Am J Kidney Dis. 2017 Oct; 70(4):522-531.
Score: 0.029
-
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2016 Dec; 68(6):873-881.
Score: 0.028
-
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar; 149(3):408-13.
Score: 0.012